newsfilter
← Latest News
GlobeNewswire·

Homology Medicines Reports Second Quarter 2022 Financial Results, Recent Highlights and Provides Business Update

- On Track for Updates on pheEDIT and juMPStart Programs by End of 2022 - - Prioritized Pipeline, Shifting Resources to HMI-103 PKU Gene Editing Trial in Adults While Pausing Enrollment in HMI-102 PKU Gene Therapy Trial Also in Adults - - Received